atai Life Sciences adds to its holding in Compass Pathways, raising its ownership interest back to 20.8%.
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
Seelos Therapeutics announces $20 million in new funding via convertible note, with an option for an additional $30 million.
Novamind Unveils New Logo and Invests in Unified Brand
Novamind announces unified branding of all subsidiaries and brands, and includes a new corporate logo.
Psychedelics-Assisted Therapy: Effective, Economical AND Imperative
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Compass study result validates industry's hope to find alternative treatments for mental health
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues.
Novamind Signs LOI to Acquire Two Mental Health Clinics in Arizona
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
MindMed announces its Q3 2021 results. Continued progress on R&D and pipeline development. Cash and equivalents of $178.6 million.
12Media34!
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
Bill aims to make Pennsylvania a national leader in psychoactive research
The bill would encourage research into psilocybin, the active ingredient in magic mushrooms.
DEA Boosts Psilocybin, MDMA And DMT Production Levels Again In Final Quotas For 2021
The Drug Enforcement Administration is again greatly increasing legal production quotas for illegal Schedule I drugs like psilocybin, MDMA and DMT.